clinical trial · NCT03790787
Drug Interaction Study Between Dorzagliatin and Empagliflozin
PatientsEmpagliflozinDorzagliatin
brief summary
This is a Phase 1, open-label, sequential, multiple-dose, drug interaction study of glucokinase activator dorzagliatin and empagliflozin in subjects with T2DM. Pharmacokinetics and pharmacodynamics when dorzagliatin and empagliflozin given alone and in combination will be studied.
started
Apr 18, 2019
primary completion
Mar 15, 2020
completion
Mar 15, 2020
last updated
Mar 24, 2025
official title
A Phase 1, Open-Label, Sequential, Multiple-Dose, Drug-Drug Interaction Study of Dorzagliatin and Empagliflozin in Subjects with Type 2 Diabetes Mellitus
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol